419 related articles for article (PubMed ID: 29556838)
1. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
van der Meijden JC; Kruijshaar ME; Harlaar L; Rizopoulos D; van der Beek NAME; van der Ploeg AT
J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838
[TBL] [Abstract][Full Text] [Related]
2. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
[TBL] [Abstract][Full Text] [Related]
3. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L; Hogrel JY; Perniconi B; Kruijshaar ME; Rizopoulos D; Taouagh N; Canal A; Brusse E; van Doorn PA; van der Ploeg AT; Laforêt P; van der Beek NAME
Neurology; 2019 Nov; 93(19):e1756-e1767. PubMed ID: 31619483
[TBL] [Abstract][Full Text] [Related]
4. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
[TBL] [Abstract][Full Text] [Related]
5. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.
de Vries JM; van der Beek NA; Hop WC; Karstens FP; Wokke JH; de Visser M; van Engelen BG; Kuks JB; van der Kooi AJ; Notermans NC; Faber CG; Verschuuren JJ; Kruijshaar ME; Reuser AJ; van Doorn PA; van der Ploeg AT
Orphanet J Rare Dis; 2012 Sep; 7():73. PubMed ID: 23013746
[TBL] [Abstract][Full Text] [Related]
6. [The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].
Molnár MJ; Borsos B; Várdi KV; Grosz Z; Sebők Á; Dézsi L; Almássy Z; Kerényi L; Jobbágy Z; Jávor L; Bidló J
Ideggyogy Sz; 2020 May; 73(05-06):151-159. PubMed ID: 32579304
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
Winkler M; von Landenberg C; Kuchenbecker K; Reimann J; Kornblum C
Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy and fatigue in adults with Pompe disease.
Güngör D; de Vries JM; Brusse E; Kruijshaar ME; Hop WC; Murawska M; van den Berg LE; Reuser AJ; van Doorn PA; Hagemans ML; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 Jun; 109(2):174-8. PubMed ID: 23603069
[TBL] [Abstract][Full Text] [Related]
10. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
11. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
12. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy.
Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M
J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213
[TBL] [Abstract][Full Text] [Related]
13. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Hundsberger T; Rösler KM; Findling O
J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
15. Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience.
Papadimas GK; Anagnostopoulos C; Xirou S; Michelakakis H; Terzis G; Mavridou I; Kararizou E; Papadopoulos C
Neuromuscul Disord; 2021 Feb; 31(2):91-100. PubMed ID: 33451932
[TBL] [Abstract][Full Text] [Related]
16. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
17. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
18. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
19. Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients.
van den Dorpel JJA; Poelman E; Harlaar L; van Kooten HA; van der Giessen LJ; van Doorn PA; van der Ploeg AT; van den Hout JMP; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):247. PubMed ID: 32928284
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
